Lv2
110 积分 2025-06-02 加入
Induced proximity pushes beyond protein degraders, as first RIPTAC moves into the clinic
1个月前
已完结
Efficacy and Safety of BL-B01D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial
1个月前
已完结
International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin–exposed High-risk Non–muscle-invasive Bladder Cancer
2个月前
已完结
Optimizing Clinical Trial Design for Patients with Non–muscle-invasive Bladder Cancer
2个月前
已完结
Clinical trial design for non-muscle-invasive bladder cancer
2个月前
已完结
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial
2个月前
已完结
Review of BCG immunotherapy for bladder cancer
2个月前
已完结
FGFR Inhibition in Urothelial Carcinoma
2个月前
已完结
SUNRISE-5: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF TAR-200 COMPARED WITH INTRAVESICAL CHEMOTHERAPY AFTER BACILLUS CALMETTE-GUÉRIN IN RECURRENT HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER
3个月前
已完结
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
4个月前
已完结
皖公网安备34019202002308
